• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Poll

POLL: Which September FDA Approval Are You Looking Forward To?

Author(s):

Dermatology Times Staff

Click here to answer this week's poll.

Which September FDA Approval Are You Looking Forward To?

Revance's daxibotulinumtoxinA for glabbelar lines; PDUFA September 8, 2022
Bristol Myers Squibb's deucravacitinib for psoriasis; PDUFA September 10, 2022
Sanofi/Regneron's dupilumab for prurigo nodularis; PDUFA September 30, 2022
Related Content
POLL: Are You Attending the Elevate-Derm West Conference?
November 6th 2024

POLL: Are You Attending the Elevate-Derm West Conference?

POLL: Are You Attending the 44th Annual Fall Clinical Dermatology Conference?
October 23rd 2024

POLL: Are You Attending the 44th Annual Fall Clinical Dermatology Conference?

Teledermatology on Par with Clinic Dermatology, New Review Finds
October 16th 2024

Teledermatology on Par with Clinic Dermatology, New Review Finds

Previewing Maui Derm NP+PA Fall 2024: Will You Be There?
September 15th 2024

Previewing Maui Derm NP+PA Fall 2024: Will You Be There?

POLL: What Are You Most Looking Forward to Learning at the 2024 Society for Pediatric Dermatology Annual Meeting?
July 11th 2024

POLL: What Are You Most Looking Forward to Learning at the 2024 Society for Pediatric Dermatology Annual Meeting?

POLL: How Comfortable Do You Feel Discussing OX40 Treatments for Atopic Dermatitis With Your Patients?
July 9th 2024

POLL: How Comfortable Do You Feel Discussing OX40 Treatments for Atopic Dermatitis With Your Patients?

© 2024 MJH Life Sciences

All rights reserved.